Novartis: abandons Alzheimer's drug trials with Amgen
(CercleFinance.com) - Novartis and Amgen said on Tuesday they would discontinue late-stage trials testing their Alzheimer's prevention drug, the latest among a series of drugmakers that have stopped developing treatments for the neurodegenerative disease.
The two companies and their partner, Banner Alzheimer's Institute, announced the decision to discontinue investigation of two pivotal Phase II/III studies on CNP520.
An assessment of data during a regular pre-planned review identified worsening in some measures of cognitive function, they said.
The Zurich-listed shares of Novartis are currently down 0.6%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The two companies and their partner, Banner Alzheimer's Institute, announced the decision to discontinue investigation of two pivotal Phase II/III studies on CNP520.
An assessment of data during a regular pre-planned review identified worsening in some measures of cognitive function, they said.
The Zurich-listed shares of Novartis are currently down 0.6%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.